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ABSTRACT
Introduction: To examine the comparative 
short-term effects of brimonidine/timolol 
and dorzolamide/timolol on ocular perfusion 
pressure and retrobulbar blood flow in patients 
with primary open angle glaucoma (OAG). 
Methods: In a prospective, randomized, double-
blind, crossover study, intraocular pressure (IOP), 
blood pressure (BP), ocular perfusion pressure 
(OPP), and retrobulbar hemodynamics were 
assessed in 15 patients with OAG (mean age 
68.1 years, eight women) with well controlled 
IOP. IOP was measured by Goldman applanation 
tonometery and color Doppler imaging was 
utilized to assess the retrobulbar blood vessels 
before and 1 month after treatment with topical 
brimonidine/timolol and dorzolamide/timolol. 
Statistical analysis was performed by Friedman 
two-way analysis of variance by ranks and
post-hoc Wilcoxon signed rank test for multiple 
comparisons with Holm’s sequential Bonferroni 
procedure. P values <0.05 were considered 
statistically significant. Results: The Friedman 
test and subsequent post-hoc analysis indicated 
that IOP, BP, OPP, and retrobulbar blood flow 
velocities did not significantly differ between 
brimonidine/timolol and dorzolamide/timolol 
after 1-month treatment administration in 
patients with OAG and well controlled IOP. 
Conclusion: In this cohort of patients with OAG, 
short-term treatment with brimonidine/timolol 
and dorzolamide/timolol results in similar effects 
on OPP and retrobulbar blood flow velocities.
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INTRODUCTION
Primary open angle glaucoma (OAG) is a 
multifactorial optic neuropathy characterized 
by progressive retinal ganglion cell death and 
visual field loss. Despite being a leading cause 
of impaired vision worldwide, the risk factors 
for OAG have not been fully defined. Elevated 
intraocular pressure (IOP) is the only currently 
treatable risk factor for OAG, although a high 
percentage of individuals with elevated IOP 
do not develop glaucoma.1 In addition, many 
patients experience glaucoma progression 
despite significantly reduced IOP, suggesting 
other factors contribute to OAG disease onset 
and progression.2-3
Over the past several decades, dozens of 
studies have linked abnormalities in ocular 
perfusion pressure (OPP) and blood flow to 
glaucomatous optic neuropathy.4 Specifically, 
blood flow deficiencies of the retinal, choroidal, 
and retrobulbar circulations have been reported 
in patients with OAG.4 In large population-based 
trials, reduced OPP has been linked to both 
the prevalence and incidence of glaucoma.5-8 
Systemic and local vascular abnormalities have 
also been linked to OAG, including arterial 
hypertension, nocturnal hypotension, optic 
disc hemorrhage, migraine, and aging of the 
vasculature.9 Mechanistically, reduced ocular 
perfusion may be secondary to IOP elevation or 
represent a primary insult in glaucoma, including 
the presence of vasospasm and/or faulty vascular 
autoregulation. At the 2009 World Glaucoma 
Association meeting10 a consensus was agreed 
that vascular dysregulation may contribute to 
the pathogenesis of glaucoma, and that low 
OPP is an independent risk factor for OAG. 
Although a wealth of pilot research has shown 
that vascular parameters are associated with 
glaucoma, their exact relationship to glaucoma 
progression remains insufficiently investigated. 
The physiological mechanisms of OAG 
therapies that reduce IOP differ, as do their 
potential to influence vascular smooth muscle.11
It is, therefore, important to consider how 
glaucoma treatments may impact OPP and 
blood flow in addition to IOP reduction. 
Dorzolamide/timolol contains a carbonic 
anhydrase inhibitor (dorzolamide) and a beta-
blocking agent (timolol). Dorzolamide/timolol 
has been previously demonstrated to produce 
increases in ocular blood flow in addition to IOP 
reduction.12 Brimonidine/timolol contains an 
alpha2-adrenergic receptor agonist (brimonidine) 
and a beta-blocking agent (timolol). The 
hemodynamic effects of brimonidine/timolol 
are currently not sufficiently established in the 
literature. 
The purpose of this investigation was to 
examine differences in short-term treatment 
of dorzolamide/timolol versus brimonidine/
timolol in terms of OPP and retrobulbar blood 
flow in patients with OAG. 
MATERIALS AND METHODS
This investigation was conducted at the 
Glaucoma Research and Diagnostic Center 
in conjunction with the Department of 
Ophthalmology and Division of Biostatistics 
at the Indiana University School of Medicine, 
Indianapolis, IN, USA. All experimental 
procedures conformed to the tenets of the 
Declaration of Helsinki and were approved 
by the institutional review board at Indiana 
University School of Medicine. Subjects signed 
informed consent prior to entry into the study. 
The study was registered with ClinicalTrials.gov 
(NCT 00811850) under the title Comparing 
Effects of Two Fixed Combinations Ophthalmic 
Solutions on Ocular Blood Flow.
A total of 15 established patients with 
documented OAG and well controlled IOP 
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participated over a period of 10 weeks in a 
prospective, double-blind, randomized crossover 
study. All participants were referred by the 
Departments of Ophthalmology at Indiana 
University and Wishard Hospitals. 
Inclusion criteria included: age 30 years or 
older; previously documented OAG in at least 
one eye, defined as characteristic glaucomatous 
visual field loss and optic nerve head damage; 
best corrected visual acuity of at least 20/40; 
and baseline IOP well controlled below
22 mmHg.
Exclusion criteria included: history of acute 
angle closure or a narrow, occludable anterior 
chamber angle by gonioscopy; history of 
chronic or recurrent inflammatory eye diseases
(eg, scleritis, uveitis); history or signs of 
intraocular trauma; any abnormality preventing 
reliable applanation tonometry; current use of 
any ophthalmic or systemic medications that 
may interfere with the investigation; and severe, 
unstable, or uncontrolled cardiovascular, renal, 
or pulmonary disease.
All subjects discontinued all hypotensive 
therapies and underwent a 3-week washout 
and timolol (twice daily) run prior to baseline 
evaluations. For each visit, IOP, blood pressure, 
radial pulse, OPP, and color Doppler imaging 
(CDI) of retrobulbar blood vessels were 
performed. Subjects were randomized to topical 
brimonidine/timolol (Combigan®, brimonidine 
tartrate 0.2%/timolol maleate 0.5% ophthalmic 
solution; Allergan, Inc., Irvine, CA, USA) or 
dorzolamide/timolol (Cosopt®, dorzolamide 
hydrochloride/timolol maleate ophthalmic 
solution; Merck & Co., Inc., Whitehouse Station, 
NJ, USA) twice daily and measurements were 
repeated after 1 month. A second 2-week timolol 
washout of the first study medication was 
followed by a second baseline examination and a 
crossover of study medications for an additional 
1-month treatment period and final evaluation. 
Compliance of drug administration was based 
upon self-reporting. 
All examinations were performed on one 
qualified study eye chosen at random by 
randomization chart. All measurements were 
performed in the same order, at the same time 
of day, and by the same examiner for each 
patient.
Measurements
Brachial artery systolic and diastolic blood 
pressure (SBP and DBP, respectively) and pulse 
were assessed after a 5-minute rest period using 
a calibrated automated sphygmomanometer 
at the beginning and end of each study visit. 
IOP was assessed using Goldmann applanation 
tonometry. OPPs were calculated as two-thirds 
mean arterial pressure minus IOP. 
CDI of the retrobulbar blood vessels was 
conducted using Philips High Definition Ima 
(HDI) 5000 Sono computed tomography (CT) 
Ultrasound System with the microvascular 
small parts clinical option (Philips Medical 
Systems, Bothell, WA, USA) with a 7.5 MHz 
linear probe as described in detail previously.13-16 
Samples of pulsed Doppler signal from within a
0.2 x 0.2 mm sample area were analyzed 
to calculate blood flow velocities in the 
retrobulbar vasculature. CDI measurements 
were taken in the ophthalmic arteries (OA), 
central retinal arteries (CRA), and nasal 
and temporal short posterior ciliary arteries
(NPCA and TPCA, respectively). In each vessel, 
peak systolic and end diastolic velocities 
(PSV and EDV, respectively) were determined 
and Pourcelot’s vascular resistive index (RI) 
was calculated (RI=[PSV-EDV]/PSV). These 
techniques have been previously shown to 
yield reproducible measurements of retrobulbar 
blood flow velocities and peripheral vascular 
resistance.13-16
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Statistical Analysis
Statistical analyses were performed using the 
SPSS statistical software package (version 18.0, 
SPSS Inc, Chicago, IL) for Microsoft Windows. 
The Friedman two-way analysis of variance by 
ranks and post-hoc Wilcoxon signed rank test 
for multiple comparisons were used to compare 
retrobulbar hemodynamic variables before and 
after dorzolamide/timolol or brimonidine/
timolol administration (four conditions). 
Holm’s sequential Bonferroni adjusted 
significance levels were used to control the 
number of multiple paired comparisons, and 
to reduce type I errors. Given that six pairwise 
comparisons were performed, the adjusted 
cutoff P values were 0.017, 0.02, 0.025, 0.033, 
0.05, and 0.1, in ascending order. Data are 
presented as mean ± SD or median (range). 
P values <0.05 were considered statistically 
significant.
RESULTS
All 15 patients (mean age 68.1 years, eight 
women) completed all study visits. Baseline 
IOP values were obtained under timolol 
washout treatment with initial IOP values
o f  13 .33 -13 .73  mmHg (3 .09 -3 .20 ) .
No statistically significant differences in OPP, 
mean arterial pressure, and heart rate were 
found between the four studied conditions 
(Friedman test; P=0.516, 0.880, 0.992, and 0.114, 
respectively). 
The Friedman test indicated that the mean 
ranks for CDI-assessed PSV, EDV, and RI in the 
CRA, NPCA, and TPCA did not significantly 
differ before and after dorzolamide/timolol or 
brimonidine/timolol administration (Tables 1 
and 2, Figures 1 and 2). A difference was 
noted in the sum of ranks of OA EDV between 
the four experimented conditions (Table 1);
however, post-hoc analysis revealed no 
difference between the two drugs (Z score=1.19, 
P=0.233). 
When comparing treatments to individual 
baselines, both dorzolamide/timolol and 
brimonidine/timolol tended to increase PSV and 
EDV in the NPCA and TPCA, with a significant 
increase for dorzolamide/timolol in both blood 
vessels (Table 3), although the changes were 
not statistically significant after conservative 
adjustment for multiple comparisons (paired 
comparison with Holm’s sequential Bonferroni 
correction). The differences between the two 
drugs were also not statistically significant 
with Holm’s sequentially rejective Bonferroni 
correction procedure. 
DISCUSSION
Primary OAG continues to be enigmatic in 
some patients, with continued progression of 
the disease, despite significantly lowered IOP. 
Vascular considerations in patients with OAG 
continue to be actively discussed,10 with ever-
increasing data to support their relevance in 
optic neuropathy. It is, therefore, important to 
establish the hemodynamic profile of glaucoma 
treatments, in addition to their effects on IOP. 
To the best of the authors’ knowledge, this is 
the first study to report results on the effects of 
brimonidine/timolol on retrobulbar blood flow 
in patients with OAG. 
To significantly impact ocular blood flow, 
topical OAG medications must penetrate 
the anterior surface of the eye, reach critical 
concentrations, and exert a physiological effect 
on the vascular tissue. Each of the different 
classes of OAG therapies maintain the potential 
to interact with vascular smooth muscle.11 
Topical medications may have a direct vascular 
interaction in ocular tissues, or may increase 
OPP by lowering IOP; thus, producing a
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net effect on the ocular circulation and possibly 
influencing OAG pathology. 
Aqueous humor secretion depends on 
the production of bicarbonate (HCO3-) in a 
reaction catalyzed by carbonic anhydrase II,17
an isoenzyme found in the nonpigmented 
ciliary epithelium. Chemically, carbonic 
anhydrase catalyzes carbon dioxide (CO2) 
interconversion to carbonic acid (H2CO3), 
which freely dissociates into HCO3- and 
protons. A blockade of carbonic anhydrase 
in local tissues reduces IOP but may also 
increase tissue CO2 concentrations and/or 
lower tissue pH, resulting in vascular dilation 
and increased blood flow.12,18 This may explain 
the physiological mechanism by which 
dorzolamide/timolol has been consistently 
shown to increase blood flow in ocular tissues 
in numerous clinical trials.12
To the best of the authors’ knowledge, there 
has been no prior published study that has 
reported on the ocular blood flow effects of 
Table 1. Friedman comparison before and after brimonidine/timolol or dorzolamide/timolol administration. Color Doppler 
imaging measurements were taken in the OA and CRA. In each vessel, PSV and EDV were determined and Pourcelot’s 
vascular RI.
Artery/measurement Experiment Mean (SD) Median (range) Z score (P value)
OA PSV (cm/s) Pre-brimonidine/timolol 23.66 (10.98) 20.60 (8.30-50.70) 3.67 (0.299)
  Post-brimonidine/timolol 24.50 (11.25) 22.10 (8.20-48.80) 
  Pre-dorzolamide/timolol 21.40 (8.28) 19.30 (7.50-39.50) 
  Post-dorzolamide/timolol 22.09 (8.25) 22.10 (6.70-38.70) 
 EDV (cm/s) Pre-brimonidine/timolol 5.16 (2.04) 5.30 (1.60-8.40) 9.98 (0.019)
  Post-brimonidine/timolol 5.83 (2.49) 5.30 (1.60-12.20) 
  Pre-dorzolamide/timolol 4.49 (1.46) 4.60 (1.60-6.60) 
  Post-dorzolamide/timolol 5.18 (2.33) 5.30 (1.20-9.40) 
 RI Pre-brimonidine/timolol 0.77 (0.09) 0.79 (0.50-0.87) 3.96 (0.265)
  Post-brimonidine/timolol 0.75 (0.08) 0.76 (0.53-0.84) 
  Pre-dorzolamide/timolol 0.77 (0.07) 0.77 (0.63-0.85) 
  Post-dorzolamide/timolol 0.77 (0.06) 0.78 (0.58-0.84) 
CRA PSV (cm/s) Pre-brimonidine/timolol 8.75 (2.40) 8.80 (4.50-13.50) 1.69 (0.640)
  Post-brimonidine/timolol 8.86 (2.19) 8.80 (6.00-13.30) 
  Pre-dorzolamide/timolol 8.29 (2.48) 8.30 (3.50-13.30) 
  Post-dorzolamide/timolol 8.81 (2.54) 8.00 (4.10-13.80) 
 EDV (cm/s) Pre-brimonidine/timolol 2.56 (1.05) 2.30 (1.30-5.30) 6.07 (0.108)
  Post-brimonidine/timolol 2.73 (0.65) 2.80 (1.80-4.00) 
  Pre-dorzolamide/timolol 2.45 (0.82) 2.30 (1.00-4.00) 
  Post-dorzolamide/timolol 2.75 (0.78) 2.80 (1.10-4.00) 
 RI Pre-brimonidine/timolol 0.71 (0.06) 0.74 (0.54-0.77) 3.83 (0.281)
  Post-brimonidine/timolol 0.70 (0.06) 0.71 (0.60-0.80) 
  Pre-dorzolamide/timolol 0.70 (0.06) 0.71 (0.56-0.80) 
  Post-dorzolamide/timolol 0.68 (0.05) 0.68 (0.60-0.80) 
CRA=central retinal artery; EDV=end diastolic velocity; OA=ophthalmic artery; PSV=peak systolic velocity; RI=resistive 
index.
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brimonidine/timolol combination in patients 
with OAG. In the current investigation, the 
authors examined how brimonidine/timolol 
combination may differ from dorzolamide/
timolol combination, an established12,19,20 
concomitant therapy, in terms of OPP and 
retrobulbar blood flow in IOP-controlled OAG 
patients. In this short-duration investigation, 
both dorzolamide/timolol and brimonidine/
timolol tended to increase blood flow velocities 
in both short posterior ciliary arteries, 
with a statistically significant increase for 
dorzolamide/timolol in both blood vessels 
compared to baseline. This is in agreement 
with the majority of previous trials involving 
dorzolamide/timolol.12 In the current analysis, 
both dorzolamide/timolol and brimonidine/
timolol increased blood flow velocities, thereby 
resulting in no statistically significant difference 
between treatments. In other comparative trials 
of dorzolamide/timolol, retinal blood flow was 
found to increase in the superficial retinal 
Table 2. Friedman comparison before and after brimonidine/timolol or dorzolamide/timolol administration. Color Doppler 
imaging measurements were taken in the NPCA and TPCA. In each vessel, PSV and EDV were determined and Pourcelot’s 
vascular RI.
Artery/measurement Experiment Mean (SD) Median (range) Z score (P value)
TPCA PSV (cm/s) Pre-brimonidine/timolol 8.47 (1.71) 8.30 (5.80-11.50) 5.26 (0.154)
  Post-brimonidine/timolol 8.52 (1.57) 8.50 (5.50-11.30) 
  Pre-dorzolamide/timolol 8.05 (1.45) 8.00 (5.00-10.30) 
  Post-dorzolamide/timolol 8.84 (1.75) 8.80 (4.50-12.00) 
 EDV (cm/s) Pre-brimonidine/timolol 2.56 (0.62) 2.30 (2.00-3.80) 6.42 (0.093)
  Post-brimonidine/timolol 2.73 (0.67) 2.80 (1.80-4.30) 
  Pre-dorzolamide/timolol 2.38 (0.71) 2.00 (1.80-4.50) 
  Post-dorzolamide/timolol 2.87 (0.95) 2.80 (1.50-5.00) 
 RI Pre-brimonidine/timolol 0.69 (0.08) 0.70 (0.49-0.81) 1.99 (0.574)
  Post-brimonidine/timolol 0.67 (0.08) 0.70 (0.48-0.78) 
  Pre-dorzolamide/timolol 0.70 (0.08) 0.71 (0.53-0.80) 
  Post-dorzolamide/timolol 0.68 (0.08) 0.67 (0.54-0.83) 
NPCA PSV (cm/s) Pre-brimonidine/timolol 7.81 (2.08) 7.50 (5.00-12.30) 6.94 (0.074)
  Post-brimonidine/timolol 8.61 (2.33) 7.50 (6.30-14.00) 
  Pre-dorzolamide/timolol 7.61 (2.28) 7.10 (4.00-11.50) 
  Post-dorzolamide/timolol 8.02 (2.51) 7.80 (4.30-12.30) 
 EDV (cm/s) Pre-brimonidine/timolol 2.41 (0.62) 2.30 (1.50-3.50) 6.38 (0.095)
  Post-brimonidine/timolol 2.63 (0.71) 2.30 (2.00-4.50) 
  Pre-dorzolamide/timolol 2.39 (0.63) 2.30 (1.50-3.50) 
  Post-dorzolamide/timolol 2.61 (0.63) 2.50 (1.50-3.80) 
 RI Pre-brimonidine/timolol 0.69 (0.05) 0.67 (0.60-0.77) 5.16 (0.160)
  Post-brimonidine/timolol 0.68 (0.04) 0.67 (0.60-0.75) 
  Pre-dorzolamide/timolol 0.68 (0.05) 0.68 (0.56-0.75) 
  Post-dorzolamide/timolol 0.67 (0.06) 0.68 (0.57-0.76) 
EDV=end diastolic velocity; NPCA=nasal short posterior ciliary artery; PSV=peak systolic velocity; RI=resistive index; 
TPCA=temporal short posterior ciliary artery.
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Figure 1. Color Doppler imaging measurements taken in 
the TPCA. In each vessel, PSV and EDV were determined 
and Pourcelot’s vascular RI. Changes in TPCA PSV (A), 
EDV (B), and RI (C) following 2-week treatment with 
brimonidine/timolol and dorzolamide/timolol. The 
fluctuations are not statistically significant. EDV=end 
diastolic velocity; PSV=peak systolic velocity; RI=resistive 
index; TPCA=temporal short posterior ciliary artery. 
Figure 2. Color Doppler imaging measurements were 
taken in the NPCA. In each vessel, PSV and EDV were 
determined and Pourcelot’s vascular RI. Changes in NPCA 
PSV (A), EDV (B), and RI (C) following 2-week treatment 
with brimonidine/timolol and dorzolamide/timolol. The 
fluctuations are not statistically significant. EDV=end 
diastolic velocity; NPCA=nasal short posterior ciliary 
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vasculature in both glaucomatous and healthy 
patients following 8 months of treatment, but 
with no effect on the retrobulbar blood vessels.19
Another study also found neither dorzolamide 
nor latanoprost had any statistically 
significantly effect on retrobulbar blood 
flow, but did find dorzolamide significantly 
decreased arteriovenous passage time in the 
superior retina, while latanoprost did not.21
Similar findings have been previously reported 
with dorzolamide/timolol compared to timolol 
monotherapy.22 As retinal microcirculation 
was not measured in the current study, it 
remains unknown if dorzolamide/timolol and 
brimonidine/timolol may differ in their effects 
on retinal capillary blood flow. 
Previous investigations of brimonidine 
(monotherapy) did not find any significant 
alterations in blood flow velocities or RI in 
the retrobulbar vessels after 2 weeks23 and 
3 months24 of treatment. The findings in the 
present study are in agreement with these prior 
studies suggesting no significant influence of 
brimonidine/timolol on the retrobulbar blood 
vessels, although a positive trend was found 
compared to timolol baseline values. One study, 
which investigated the ocular hemodynamic 
effects of brimonidine/timolol versus placebo 
in patients with ocular hypertension, reported a 
significant decrease of CRA RI that the authors 
suggested may be explained by a concurrent 
decrease in IOP, whereas placebo showed no 
significant changes after 3 months.25 The 
authors of this study acknowledged that 
the short-duration administration may be 
insufficient to elicit potential differing effects 
between brimonidine/timolol and dorzolamide/
timolol, and that well controlled IOP glaucoma 
patients may not be representative of high 
pressure OAG patients. Additional research 
into the possible effects of brimonidine/timolol 
on other ocular vascular beds, including the 
retinal microcirculation, is suggested before a 
definitive conclusion can be reached.
In this study’s group of patients with OAG 
there were also no statistically significant 
differences between brimonidine/timolol 
versus dorzolamide/timolol when comparing 
the mean change between treatments from 
baseline in the effects on blood pressure or 
calculated OPPs. A similar effect on IOP was 
observed between treatments in the current 
investigation, though the study was not 
designed for evaluating IOP-lowering efficacy. 
Table 3. Results of Wilcoxon signed rank multiple comparisons expressed in P values. Color Doppler imaging measurements 
were taken in the OA, CRA, NPCA, and TPCA. In each vessel, PSV and EDV were determined and Pourcelot’s vascular RI.
 TPCA NPCA
Comparison PSV EDV PSV EDV
Pre-brimonidine/timolol vs. post-brimonidine/timolol 0.779 0.103 0.155 0.167
Pre-dorzolamide/timolol vs. post-dorzolamide/timolol 0.025 0.031 0.035 0.020
Pre-brimonidine/timolol vs. pre-dorzolamide/timolol 0.271 0.171 0.571 0.889
Pre-brimonidine/timolol vs. post-dorzolamide/timolol 0.257 0.278 0.675 0.104
Pre-dorzolamide/timolol vs. post-brimonidine/timolol 0.306 0.049 0.099 0.235
Post-brimonidine/timolol vs. post-dorzolamide/timolol 0.572 0.683 0.243 0.968
CRA=central retinal artery; EDV=end diastolic velocity; NPCA=nasal short posterior ciliary artery; OA=ophthalmic 
artery; PSV=peak systolic velocity; RI=resistive index; TPCA=temporal short posterior ciliary artery.
Dorzolamide/timolol significantly increased TPCA and NPCA PSV and EDV; however, none of the observed differences 
were statistically significant based on Holm’s sequential Bonferroni adjusted significance levels.
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While brimonidine and timolol have previously 
been shown to significantly decrease SBP, DBP, 
and diastolic perfusion pressure in a study by 
Quaranta et al.,26 no significant effects were 
observed between treatments or from baseline 
in terms of blood pressure or OPPs. Results 
from the current study are similar to Liu, who 
previously reported brimonidine twice daily 
caused no changes in OPPs.27 The differences 
between the findings of the present study and 
the results from Quaranta et al.26 and Liu et al.27 
may be due to the dosing regimen, treatment 
duration (4 weeks in the current investigation 
and in the Liu et al. study,27 6 weeks in the 
Quaranta et al. study26), specific measurement 
timepoints, patient populations (current study 
established OAG compared to normal tension 
glaucoma,27 and newly diagnosed26), and/or 
coadministration of brimonidine with timolol. 
There is currently insufficient agreement to 
conclude that brimonidine/timolol influences 
blood pressure or OPP based upon these 
combined investigations. The results of the 
present study suggest brimonidine/timolol does 
not negatively impact OPP in established IOP-
controlled glaucoma patients. 
The current study had several limitations. 
First, the study duration was only 1 month 
for each therapy and may not reflect the long-
term effects of chronic glaucoma management 
under either treatment. Second, due to the 
study duration, changes in visual field or optic 
nerve structure for either treatment were not 
evaluated. While the current study group had 
well controlled IOP, the results of this study 
may not be fully applicable to low-pressure 
glaucoma patients. Retinal capillary blood flow 
or diurnal fluctuations in IOP, OPP, or blood 
flow for these therapies was also not assessed, 
which recent research has indicated may be 
linked to glaucoma progression.28 Future studies 
that monitor risk factor fluctuations throughout 
the 24-hour period may reveal differences not 
seen in the present study. Although adequate 
based upon similar studies of dorzolamide, a 
larger patient sample may further differentiate 
results. Finally, each imaging technology 
has inherit limitations; within the current 
investigation, CDI evaluated blood flow 
velocities and calculated vascular resistance but 
did not analyze direct flow assessments due to a 
lack of blood vessel diameter.13-16
CONCLUSION
In summary, both brimonidine/timolol and 
dorzolamide/timolol therapies tended to 
increase OPP and retrobulbar blood flow, with 
no statistically significant differences between 
treatments after 1 month in patients with OAG 
and well controlled IOP.
ACKNOWLEDGMENTS
This study was funded by Allergan, Inc. DAH 
and JMW, who are coauthors, are employees 
of Allergan, who market the drug Combigan®. 
While they had no influence on the study 
results, DAH and JMW wanted to ensure 
this was disclosed. BS, AH, RE, LC, MMS, JA, 
DR, LA, and YS are affiliated with Indiana 
University School of Medicine Department 
of Ophthalmology and have no competing 
financial interests. BS is the guarantor for this 
article, and takes responsibility for the integrity 
of the work as a whole.
Open Access. This article is distributed 
under the terms of the Creative Commons 
Attribution Noncommercial License which 
permits ant noncommercial use, distribution, 
and reproduction in any medium, provided
the original author(s) and source are
credited.
62 Adv Ther (2012)  29(1):53-63.
REFERENCES
1. Hollows RC, Graham PA. Intraocular pressure, 
glaucoma, and glaucoma suspects in a defined 
population. Br J Ophthalmol. 1996;50:570-577.
2. Heijl A, Leske MC, Bengtsson B, et al. Reduction 
of intraocular pressure and glaucoma progression: 
results from the Early Manifest Glaucoma Trial. 
Arch Ophthalmol. 2002;120:1268-1279.
3. Collaborative Normal-Tension Glaucoma Study 
Group. Comparison of glaucomatous progression 
between untreated patients with normal-tension 
glaucoma and patients with therapeutically 
reduced intraocular pressure. Am J Ophthalmol. 
1998;126:487-497.
4. Harris A, Kagemann L, Ehrlich R, Rospigliosi C, 
Moore D, Siesky B. Measuring and interpreting 
ocular blood flow and metabolism in glaucoma. 
Can J Ophthalmol. 2008;43:328-336. 
5. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt 
JC. Hypertension, perfusion pressure, and primary 
open-angle glaucoma. A population-based 
assessment. Arch Ophthalmol. 1995;113:216-221.
6. Quigley HA, West SK, Rodriguez J, Munoz B, Klein 
R, Snyder R. The prevalence of glaucoma in a 
population-based study of Hispanic subjects: Proyecto 
VER. Arch Ophthalmol. 2001;119:1819-1826.
7. Bonomi L, Marchini G, Marraffa M, Bernardi 
P, Morbio R, Varotto A. Vascular risk factors for 
primary open angle glaucoma: the Egna-Neumarkt 
Study. Ophthalmology. 2000;107:1287-1293.
8. Leske MC, Wu SY, Nemesure B, Hennis A. Incident 
open-angle glaucoma and blood pressure. Arch 
Ophthalmol. 2002;120:954-959.
9. Moore D, Harris A, Wudunn D, Kheradiya N, 
Siesky B. Dysfunctional regulation of ocular blood 
flow: a risk factor for glaucoma? Clin Ophthalmol. 
2008;2:849-861.
10. Weinreb RN, Harris A, eds. Ocular Blood Flow 
in Glaucoma: The 6th Consensus Report of the 
World Glaucoma Association. Amsterdam: Kugler 
Publications; 2009. 1-159.
11. Costa VP, Harris A, Stefánsson E, et al. The effects of 
antiglaucoma and systemic medications on ocular 
blood flow. Prog Retin Eye Res. 2003;22:769-805. 
12. Siesky B, Harris A, Brizendine E, et al. Literature 
review and meta-analysis of topical carbonic 
anhydrase inhibitors and ocular blood flow. Surv 
Ophthalmol. 2009;54:33-46. 
13. Harris A, Sergott RC, Spaeth GL, Katz JL, 
Shoemaker JA, Martin BJ. Color Doppler analysis 
of ocular vessel blood velocity in normal-tension 
glaucoma. Am J Ophthalmol. 1994;118:642-649.
14. Williamson TH, Harris A. Color Doppler ultrasound 
imaging of the eye and orbit. Surv Ophthalmol. 
1996;40:255-267.
15. Harris A, Williamson TH, Martin B, et al. Test/
retest reproducibility of color Doppler imaging 
assessment of blood flow velocity in orbital vessels. 
J Glaucoma. 1995;4:281-286.
16. Quaranta L, Harris A, Donato F, Cassamali M, 
Semeraro F, Nascimbeni G, et al. Color Doppler 
imaging of ophthalmic artery blood flow 
velocity: a study of repeatability and agreement. 
Ophthalmology. 1997;104:653-658.
17. Macknight AD, McLaughlin CW, Peart D, Purves 
RD, Carré DA, Civan MM. Formation of the 
aqueous humor. Clin Exp Pharmacol Physiol. 
2000;27:100-106.
18. Taki K, Kato H, Endo S, Totsuka K. Cascade of 
acetazolamide-induced vasodilatation. Res Comm 
Mol Path Pharmacol. 1999;103:240-248.
19. Siesky B, Harris A, Kagemann L, et al. Ocular blood 
flow and oxygen delivery to the retina in primary 
open-angle glaucoma patients: the addition 
of dorzolamide to timolol monotherapy. Acta 
Ophthalmol. 2010;88:142-149.
20. Januleviciene I, Ehrlich R, Siesky B, Nedzelskiené 
I, Harris A. Visual function, optic nerve structure, 
and ocular blood flow parameters after 1 year of 
glaucoma treatment with fixed combinations. Eur 
J Ophthalmol. 2009;19:790-797.
21. Harris A, Migliardi R, Rechtman E, Cole CN, 
Yee AB, Garzozi HJ. Comparative analysis of the 
effects of dorzolamide and latanoprost on ocular 
hemodynamics in normal tension glaucoma 
patients. Eur J Ophthalmol. 2003;13:24-31.
22. Harris A, Jonescu-Cuypers CP, Kagemann L, et al. 
Effect of dorzolamide timolol combination versus 
timolol 0.5% on ocular bloodflow in patients with 
primary open-angle glaucoma. Am J Ophthalmol. 
2001;132:490-495.
23. Lachkar Y, Migdal C, Dhanjil S. Effect of brimonidine 
tartrate on ocular hemodynamic measurements. 
Arch Ophthalmol. 1998;116:1591-1594.
24. Inan UU, Ermis SS, Yucel A, Oztürk F. The effects of 
latanoprost and brimonidine on blood flow velocity 
of the retrobulbar vessels: a 3-month clinical trial. 
Acta Ophthalmol Scand. 2003;81:155-160.
Adv Ther (2012)  29(1):53-63. 63
25. Puerto-Hernández B, Rebolleda G, García-Pérez JL, 
Muñoz-Negrete FJ, González-Gordaliza C. Effect on 
ocular blood flow of Combigan® versus placebo in 
patients with ocular hypertension. Arch Soc Esp 
Oftalmol. 2011;86:42-46.
26. Quaranta L, Gandolfo F, Turano R, et al. Effects of 
topical hypotensive drugs on circadian IOP, blood 
pressure, and calculated diastolic ocular perfusion 
pressure in patients with glaucoma. Invest 
Ophthalmol Vis Sci. 2006;47:2917-2923.
27. Liu CJ, Cheng CY, Ko YC, Hsu WM. Diurnal 
intraocular pressure and blood pressure 
with two dosing regimens of brimonidine in 
normal tension glaucoma. J Chin Med Assoc. 
2004;67:465-471.
28. Sung KR, Lee S, Park SB, et al. Twenty-four 
hour ocular perfusion pressure fluctuation and 
risk of normal-tension glaucoma progression. 
Invest Ophthalmol Vis Sci. 2009;50:5266-
5274.
